Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: Relationship to clinical data

Journal of the Neurological Sciences

Volumn 170, Issue 2, 1999, Pages 90-95

  Ihara, Yuetsu ^a   Chuda, Dasaki ^b   Kuroda, Shigetoshi ^c   Hayabara, Toshiyuki ^a  

^a National Hospital Organization   (Japan)

^b Japanese Red Cross Okayama Hospital   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Free radical; Oxidative stress; Parkinson's disease; Pathogenesis; Superoxide dismutase (SOD); Therapy

Indexed keywords

BROMOCRIPTINE; HYDROXYL RADICAL; PERGOLIDE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; NEUROPROTECTION; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032748301     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00192-6     Document Type: Article

References (16)

1. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44(Suppl 1):72-84.
2. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-43.
3. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 1983;19(Suppl):89-103.
4. Gatto EM, Carreraas MC, Pargament GA, Riobo NA, Reides C, Repetto M, Pardal MMF, Llesuy S, Poderoso JJ. Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease. Mov Disord 1996;11:261-7.
5. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-8.
6. Nishibayashi S, Asanuma M, Kohno M, Gómez-Vargas M, Ogawa N. Scavenging effects of dopamine agonist on nitric oxide radicals. J Neurochem 1996;67:2208-11.
7. Gassen M, Glinka Y, Pinchasi B, Youdim MBH. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996;308:219-25.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
9. Markland SL. Distribution of Cu,Zn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluid. Acta Physiol Scand 1980;492:19-23.
10. Nicklas WJ, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine. Life Sci 1985;36:2503-8.
11. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, Parker Jr. WD. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-71.
12. Ihara Y, Kibata M, Hayabara T, Katayama S, Konishi H, Miura K, Kohno M, Yokoi I, Mori A. Free radicals in the cerebrospinal fluid are associated with neurological disorders including mitochondrial encephalomyopathy. Biochem Mol Biol Int 1997;42:937-47.
13. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-55.
14. Benecke R, Strümper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-5.
15. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, O'Brien JF, Nickander KK. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology 1996;46:796-801.
16. Clow A, Hussain T, Glover V, Sandler M, Walker M, Dexter D. Pergolide can induce soluble superoxide dismutase in rat striata. J Neural Transm 1992;90:27-31.